Less traumatic surgery

Article

Rapid technology advancements have given narrow gauge surgery the edge in diabetic cases

Vitrectomy has been proven as an effective treatment for patients with proliferative diabetic retinopathy (PDR) and many surgeons are now using narrow gauge instrumentation to perform the surgery. However, previous literature has revealed some potential disadvantages to the technique and it has been questioned whether narrow gauge surgery is associated with an increased rate of peripheral retinal break formation in macular surgery and also of relevance, a lower success rate in retinal reattachment surgery than 20G surgery.1,2

Achieving the surgical aims

To examine the incidence of retinal break formation in patients being treated for PDR, Dr Steel and colleagues retrospectively reviewed a group of 170 eyes. Half of the eyes comprised the control group and underwent conventional 20G surgery and the other half were treated with 23G transconjunctival vitrectomy surgery.

"We analysed a variety of factors in the case mix to see if the groups could be compared in a meaningful way including basic demographics, for example, it is known younger patients have a higher incidence of retinal break formation during diabetic vitrectomy, as well as a variety of metabolic indicators (e.g., HbAic)," added Dr Steel. "We also looked at the surgery performed - hence analysed the proportion of combined cases and in particular and importantly the extent and position of vitreoretinal adhesion, which defines the complexity of the cases."

Dr Steel reported that while he was transitioning from using 20G to 23G surgery he continued to perform the former technique on complex cases. Therefore, he excluded patients that were operated on during that period from the study.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.